Avo In R/R And Previously Untreated MCL

This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in this study are: * Acalabrutinib * Venetoclax * Obinutuzumab

Trial Details

NCT ID
NCT04855695
Phase
PHASE1 / PHASE2
Sponsor
Austin I Kim
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Acalabrutinib
  • Venetoclax
  • Obinutuzumab
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Participants must meet the following criteria on screening examination to be eligible to participate in the study:
  • Participants must have histologically determined mantle cell lymphoma with pathologic review at the participating institutions, that has either:
  • Relapsed or primary refractory after at least one line of therapy including anti-CD20 monoclonal antibody treatment (part A) or; Had no previous an…
  • Participants in part A, relapsed or refractory following prior therapy, may have had a prior autologous or allogeneic stem cell transplant and may …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →